ArticleMolecular therapy. Advances2026
Preclinical evaluation of AAV2 anti-VEGF gene therapy using scFv for choroidal neovascularization.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-chain variable fragments (scFvs) have been proposed as efficient therapeutic cargoes for gene therapy. However, their safety and efficacy in clinical settings remain to be fully established. In this study, we constructed a recombinant adeno-associated virus 2 (AAV2) vector encoding an anti-VEGF scFv to inhibit choroidal neovascularization (CNV), and evaluated its efficacy, biodistribution, and safety in non-human primates (NHPs) and chinchilla rabbits. Pharmacological studies demonstrated sustained inhibition of neovascularization and vascular leakage both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.